Von Willebrand factor propeptide to antigen ratio in acquired thrombotic thrombocytopenic purpura

Journal of Thrombosis and Haemostasis

Volumn 10, Issue 4, 2012, Pages 728-730

  Stufano, F ^a   La Marca, S ^a   Pontiggia, S ^a   Musallam, K M ^a   Peyvandi, F ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; PROTEIN PRECURSOR; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR; VON WILLEBRAND FACTOR PROPEPTIDE;

ADOLESCENT; ADULT; AGED; BLOOD SAMPLING; CHILD; CONTROLLED STUDY; FEMALE; HUMAN; LABORATORY TEST; LETTER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; REMISSION; SCHOOL CHILD; THROMBOTIC THROMBOCYTOPENIC PURPURA;

ADAM PROTEINS; ADOLESCENT; ADULT; AGED; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CHILD; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; ITALY; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROTEIN PRECURSORS; PURPURA, THROMBOTIC THROMBOCYTOPENIC; RECURRENCE; REGISTRIES; SEVERITY OF ILLNESS INDEX; VON WILLEBRAND FACTOR; YOUNG ADULT;

EID: 84859201374     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2012.04642.x     Document Type: Letter

References (18)

1. Sadler JE. Biochemistry and genetics of von Willebrand factor. Annu Rev Biochem 1998; 67: 395-424.
2. Wagner DD. Cell biology of von Willebrand factor. Annu Rev Cell Biol 1990; 6: 217-46.
3. Borchiellini A, Fijnvandraat K, ten Cate JW, Pajkrt D, van Deventer SJ, Pasterkamp G, Meijer-Huizinga F, Zwart-Huinink L, Voorberg J, van Mourik JA. Quantitative analysis of von Willebrand factor propeptide release in vivo: effect of experimental endotoxemia and administration of 1-deamino-8-D-arginine vasopressin in humans. Blood 1996; 88: 2951-8.
4. Federici AB. VWF propeptide: a useful marker in VWD. Blood 2006; 108: 3229-30.
5. van Mourik JA, Boertjes R, Huisveld IA, Fijnvandraat K, Pajkrt D, van Genderen PJ, Fijnheer R. von Willebrand factor propeptide in vascular disorders: a tool to distinguish between acute and chronic endothelial cell perturbation. Blood 1999; 94: 179-85.
6. Romani De Wit T, Fijnheer R, Brinkman HJ, Kersting S, Hene RJ, van Mourik JA. Endothelial cell activation in thrombotic thrombocytopenic purpura (TTP): a prospective analysis. Br J Haematol 2003; 123: 522-7.
7. Haberichter SL, Balistreri M, Christopherson P, Morateck P, Gavazova S, Bellissimo DB, Manco-Johnson MJ, Gill JC, Montgomery RR. Assay of the von Willebrand factor (VWF) propeptide to identify patients with type 1 von Willebrand disease with decreased VWF survival. Blood 2006; 108: 3344-51.
8. Schooten CJ, Tjernberg P, Westein E, Terraube V, Castaman G, Mourik JA, Hollestelle MJ, Vos HL, Bertina RM, Berg HM, Eikenboom JC, Lenting PJ, Denis CV. Cysteine-mutations in von Willebrand factor associated with increased clearance. J Thromb Haemost 2005; 3: 2228-37.
9. Habe K, Wada H, Ito-Habe N, Hatada T, Matsumoto T, Ohishi K, Maruyama K, Imai H, Mizutani H, Nobori T. Plasma ADAMTS13, von Willebrand factor (VWF) and VWF propeptide profiles in patients with DIC and related diseases. Thromb Res 2011; DOI:
10. Zhou Z, Nguyen TC, Guchhait P, Dong JF. von Willebrand factor, ADAMTS-13, and thrombotic thrombocytopenic purpura. Semin Thromb Hemost 2010; 36: 71-81.
11. Lotta LA, Mariani M, Consonni D, Mancini I, Palla R, Maino A, Vucelic D, Pizzuti M, Mannucci PM, Peyvandi F. Different clinical severity of first episodes and recurrences of thrombotic thrombocytopenic purpura. Br J Haematol 2010; 151: 488-94.
12. Newman DJ, Henneberry H, Price CP. Particle enhanced light scattering immunoassay. Ann Clin Biochem 1992; 1: 22-42.
13. Peyvandi F, Lavoretano S, Palla R, Feys HB, Vanhoorelbeke K, Battaglioli T, Valsecchi C, Canciani MT, Fabris F, Zver S, Reti M, Mikovic D, Karimi M, Giuffrida G, Laurenti L, Mannucci PM. ADAMTS13 and anti-ADAMTS13 antibodies as markers for recurrence of acquired thrombotic thrombocytopenic purpura during remission. Haematologica 2008; 93: 232-9.
14. Budde U, Schneppenheim R, Plendl H, Dent J, Ruggeri ZM, Zimmerman TS. Luminographic detection of von Willebrand factor multimers in agarose gels and on nitrocellulose membranes. Thromb Haemost 1990; 63: 312-15.
15. Lotta LA, Lombardi R, Mariani M, Lancellotti S, De Cristofaro R, Hollestelle MJ, Canciani MT, Mannucci PM, Peyvandi F. Platelet reactive conformation and multimeric pattern of von Willebrand factor in acquired thrombotic thrombocytopenic purpura during acute disease and remission. J Thromb Haemost 2011; 9: 1744-51.
16. Ito-Habe N, Wada H, Matsumoto T, Ohishi K, Toyoda H, Ishikawa E, Nomura S, Komada Y, Ito M, Nobori T, Katayama N. Elevated von Willebrand factor propeptide for the diagnosis of thrombotic microangiopathy and for predicting a poor outcome. Int J Hematol 2011; 93: 47-52.
17. Mannucci PM, Canciani MT, Forza I, Lussana F, Lattuada A, Rossi E. Changes in health and disease of the metalloprotease that cleaves von Willebrand factor. Blood 2001; 98: 2730-5.
18. Andersson HM, Siegerink B, Luken BM, Crawley JT, Algra A, Lane DA, Rosendaal FR. High VWF, low ADAMTS13 and oral contraceptives increase the risk of ischemic stroke and myocardial infarction in young women. Blood 2012; 119: 1555-60.